[9]FiftyPercentofPatientswithUlcerativeColitisTreatedwithMirikizumabAchievedClinicalRemissionatOneYearinLilly'sPivotalPhase3Study.RetrievedMay24,2022,fromhttps://www.prnewswire.com/news-releases/fifty-percent-of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.html
[10]PfizerAnnouncesPositiveTop-lineResultsfromYearlongPhase3TrialofEtrasimodinUlcerativeColitis,UnderscoringBest-in-ClassPotential.RetrievedMarch29,2022,fromhttps://www.businesswire.com/news/home/20220329005198/en
[11]MerckAnnouncesPositiveTop-lineResultsfromPivotalPhase3STELLARTrialEvaluatingSotaterceptfortheTreatmentofAdultswithPulmonaryArterialHypertension(PAH).RetrievedOctober10,2022,fromhttps://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-stellar-trial-evaluating-sotatercept-for-the-treatment-of-adults-with-pulmonary-arterial-hypertension-pah/
- 2022年循夢前行，2023年前路可期
- 2023年跨年的斷想
- 2023年元旦跨年，精選30句精選朋友祝福語送給你，愿所求皆圓滿
- 名單公布！國家藥監局批準！
- N95口罩的 “N” 是啥意思？
- 奮進新征程 共筑健康夢——《保健時報》2023年新年寄語
- 默沙東公司新冠病毒治療藥物莫諾拉韋膠囊在中國獲批
- 到2023年，奉勸各位男性朋友們：身上這個部位得好好保養了！
- 東昌婦幼獲批成為殘疾評定機構并開展首次殘疾人評定工作
- 第二款進口新冠口服藥獲批上市，默沙東能填補輝瑞緊缺困局嗎